logo-loader
RNS
4basebio PLC

4basebio Plc - Appointment of Chief Financial Officer and Board Changes

4basebio PLC

("4basebio" or the "Company")

Appointment of Chief Financial Officer and Board Changes

,Cambridge, UK14 May 2026–4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the appointment of as Chief Financial Officer, with effect from . Richard takes over the role from , who stepped down from the Board earlier this year and remained working with the Company over the orderly handover period.Richard BungayDavid RothJuly 2026

Richard is an accomplished leader with over 30 years’ senior finance and strategic experience within the pharmaceutical and biotechnology sector, leading both public and private companies from research through all clinical phases, regulatory approval and commercialisation. He joins 4basebio from Sitala Bio Limited, a -based private biotech where he helped lead a strategic repositioning of the business, working closely with the CEO and board to raise a signficant Series A round and execute an in-licencing deal with Fosun Pharma for up to .UK$670m

Richard’s prior roles include CEO and CFO at Diurnal Group plc, where he led its acquisition by Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in 2022 at a 147% one-day premium, CEO and CFO at Mereo Biopharma Group plc (NASDAQ: MREO), where he helped in-license a portfolio from Novartis and subsequently completed its AIM IPO, and CFO at Verona Pharma (then listed on the London Stock Exchange, now a subsidiary of Merck & Co) where he helped recapitalise the company.

Earlier in his career Richard was the Director of Corporate Communications and Strategic Planning at Celltech Group plc, a -listed FTSE-100/250 company where he helped execute its acquisition by UCB for £1.5bn.London

Richard is currently a Non-executive Director ofChroma Therapeutics Ltd. He qualified as a Chartered Accountant with Deloitte and has a First Class degree in Chemistry from Nottingham University.

Board Changes

Further to the above, Mr. , Non-executive Director and 2invest AG’s Board appointee, and Mr. , Non-executive Director, have stepped down from the BoardAlexander LinkAlan Maluswith effect from due to other professional commitments.31 May 2026Dr. , Non-executive Director and former CEO of the Company will take over Mr Link’s role as the Board’s appointee of 2invest AG. It is the intention that Mr. , representing M&G, will replace , subject to the completion of due diligence and regulatory approval.Heikki LanckrietCornel ChiriacMr. MalusThe Directors would like to take this opportunity to thank and for their contributions to the Board during their tenures.Mr. LinkMr. Malus

Dr , ChiefAmy WalkerExecutive Officer of 4basebio, said:“Richard has had a long and accomplished career in the industry, bringing significant experience with high growth public and private companies; we are thrilled that he has decided to join 4basebio. 4basebio is transitioning into a phase of accelerated commercial growth, and his strategic and financial expertise will be invaluable to support us on this journey. Richard’s appointment completes the build out of the senior leadership team to help us scale our operations to meet the growing need for high quality synthetic DNA products for advanced therapies and personalised medicines.”

, Chief Financial Officer at 4basebio, added:Richard Bungay“I’ve been following 4basebio’s progress for several years and have been impressed by what the team has achieved in such a short time. I look forward to working with Amy and the wider team to support the Company’s continued growth and help realise the growth potential of this exciting business as it seeks to establish a ledership position in the manufacturing of next-generation therapeutics.”

For further enquiries, please contact:

About 4basebio

4basebio (AIM: 4BB) is a -based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.Cambridge

For more information, visit.4basebio.com

--          appointed as CFO, bringing a strong track record
        in fundraising, M&A and partnering for listed and private companies,
        including two major exits and over  raisedRichard Bungay$400m
4basebio PLC                                           +44 (0)12 2396 7943

    Dr , CEO

      Cairn Financial Advisers LLP (Nominated Adviser)     +44 (0)20 7213 0880

     /  / 

      Cavendish Capital Markets Limited (Joint Broker)     +44 (0)20 7220 0500

     / 

       RBC Capital Markets (Joint Broker)                  +44 (0)20 7653 4000

     / 

    ICR Healthcare (Media and Investor Relations)          +44 (0)203 707 5700

      /Amy WalkerJo TurnerSandy JamiesonEd DownesGeoff NashNigel BirksKathryn DeeganMatthew CoakesMary-Jane ElliottJessica Hodgson



NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read